Research Activity – Page 3

Genentech (Roche) Signs $420 Million Deal With OMass Therapeutics for Preclinical IBD Program

1 week ago talkbio0Tagged Drug Discovery, genentech, Inflammatory Bowel Diseases, milestone payments, OdyssION platform, OMass, Partnership, preclinical program, Roche (company), small molecule therapy

Genentech; Roche; OMass Therapeutics; inflammatory bowel disease (IBD); preclinical program; biotech partnership; OdyssION platform; small molecule therapy; drug discovery; milestone payments

Zymeworks Halts Development of ZW171 T-cell Engager After Phase 1 Trial Assesses Benefit-Risk Profile

1 week ago talkbio0Tagged benefit-risk profile, Clinical Trials, Dose-Limiting, Drug Development, Malignant Neoplasms, mesothelin, T-Cell engager, Toxicity aspects, ZW171, Zymeworks

Zymeworks; ZW171; T-cell engager; mesothelin; cancer; clinical trial; drug development; benefit-risk profile; dose-limiting toxicity

J&J Halts Phase 2a Rheumatoid Arthritis Program for Imaavy (Nipocalimab) after Lackluster Results

2 weeks ago talkbio0Tagged Autoimmune Diseases, Clinical Research, Clinical trial failure, daisy, Imaavy, Johnson and Johnson, Nipocalimab, Phase 2a Trial, Rheumatoid Arthritis

Johnson & Johnson; Imaavy; nipocalimab; rheumatoid arthritis; Phase 2a trial; DAISY study; clinical trial failure; anti-TNFα therapy; autoimmune diseases

Outlook Therapeutics Faces New FDA Setback for First Ophthalmic Avastin Formulation

2 weeks ago talkbio0Tagged AMD, Attitude, Avastin, bevacizumab, Blackfoot language, Clinical Trials, Eight, Glycogen storage disease type II, Lytenava, New-onset refractory status epilepticus, ophthalmic formulation, Rejection, resubmission, United States Food and Drug Administration

Outlook Therapeutics; Avastin; bevacizumab; Lytenava; wet AMD; FDA rejection; NORSE EIGHT; BLA resubmission; ophthalmic formulation; clinical trial

FDA Considers Noninvasive Endpoint for MASH Trials, Boosts Biotech Shares

2 weeks ago talkbio0Tagged Altimmune, Biological Markers, Clinical Trials, Inventiva, Liver diseases, Madrigal Pharmaceuticals, MASH, Noninvasive Endpoint, stocks, United States Food and Drug Administration, Viking Therapeutics

FDA; noninvasive endpoint; liver disease; MASH; clinical trials; biomarker; biotech stocks; Madrigal Pharmaceuticals; Viking Therapeutics; Inventiva; Altimmune

Wugen Nabs $115M for Pivotal Study of Allogeneic CAR-T

2 weeks ago talkbio0Tagged Allogeneic, CAR-T, Clinical Trials, fratricide-resistant, T-cell malignancies, Wugen

Wugen; CAR-T; allogeneic; off-the-shelf therapy; fratricide-resistant; funding; pivotal trial; T-cell malignancies

Eli Lilly Highlights Verzenio’s Survival Benefit Amid Novartis Competition in Early Breast Cancer

2 weeks ago talkbio0Tagged Adjuvant Therapy, Clinical Trials, eli lilly, HER2-, HR+, Kisqali, Malignant neoplasm of breast, Novartis, Overall Survival, Verzenio

Verzenio; Eli Lilly; Novartis; Kisqali; early breast cancer; overall survival; adjuvant therapy; HR+; HER2-; clinical trial

Vinay Prasad Returns to the FDA With Fewer Titles and a Lower Profile

2 weeks ago talkbio0Tagged Center for Biologics Evaluation and Research, gene therapy, Lower Profile, Prasad, research, Return to (contextual qualifier) (qualifier value), Titles, United States Food and Drug Administration, vaccine regulation, Vinay

Vinay Prasad; FDA; return; Center for Biologics Evaluation and Research (CBER); fewer titles; lower profile; gene therapy; vaccine regulation

Who Is Making AI Work in Drug R&D in 2025?

2 weeks ago talkbio0Tagged Advice, Aortic Valve Insufficiency, Big Pharma, biopharma startups, Clinical Trials, Drug Development, Efficiency, Precision Medicine, United States Food and Drug Administration

AI drug discovery; Big Pharma; biopharma startups; clinical trials; FDA guidance; personalized medicine; drug development efficiency

Recent Advances: AI in Life Sciences—Reimagining Teams, Technology, and Partnerships

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Biological Science Disciplines, Data Integration, Drug Discovery, Generative AI, language models, Precision Medicine, strategic partnerships, team transformation, technology innovation

AI in life sciences; generative AI; large language models; team transformation; technology innovation; strategic partnerships; drug discovery; personalized medicine; data integration